Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.

Business Wire • Feb 23, 2026

Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Fourth Quarter and Year-End 2025 Financial Results and Host Conference Call on February 25, 2026.

Business Wire • Feb 18, 2026

Mirum Pharmaceuticals, Inc. (MIRM) Earnings Expected to Grow: What to Know Ahead of Q4 Release

Mirum Pharmaceuticals (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 18, 2026

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Business Wire • Feb 11, 2026

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

TORONTO--(BUSINESS WIRE)--Health Canada Authorizes Mirum's LIVMARLI® for the Treatment of Cholestatic Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis.

Business Wire • Feb 5, 2026

Mirum Pharmaceuticals Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

TORONTO--(BUSINESS WIRE)--Mirum Announces Health Canada Authorization of LIVMARLI® Tablet Formulation for the Treatment of Cholestatic Pruritus in Alagille Syndrome.

Business Wire • Feb 5, 2026

Top 3 Health Care Stocks That May Implode In Q1

As of Feb. 2, 2026, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.

Benzinga • Feb 2, 2026

Is Mirum Pharmaceuticals on a Strong Path to Profitability?

Mirum Pharmaceuticals was profitable in the third quarter. However, top-line growth for the midcap biotech will slow this year.

The Motley Fool • Jan 31, 2026

Is Mirum Pharmaceuticals About to Soar in 2026?

Mirum Pharmaceuticals is at an inflection point. The company's sales are growing fast, led by the success of Livmarli.

The Motley Fool • Jan 27, 2026

Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Completes Acquisition of Bluejay Therapeutics, Expanding Global Leadership in Rare Disease.

Business Wire • Jan 26, 2026